Physician profile
John G Passarelli
NPI 1679682702
$14,581.67
in general payments reported to CMS, 2019-2025
25 companies · $1,865 in 2025
The $1,865 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,253 · 2020: $767 · 2021: $1,661 · 2022: $2,560 · 2023: $2,543 · 2024: $2,933 · 2025: $1,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,275 · Long Term Medical Supply Or Device Loan: $48.00 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,275.16 |
| Long Term Medical Supply Or Device Loan | $48.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,226.17 | 2019-2025 | Clareon, Eysuvis, Tryptyr |
| Abbvie INC. | $2,033.36 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $1,196.85 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Allergan, INC. | $1,161.68 | 2019-2022 | |
| Ocular Therapeutix, INC. | $1,145.45 | 2019-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $632.08 | 2019-2025 | Veritas Vision System, Catalys System, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $626.11 | 2020-2025 | Cequa |
| Oyster Point Pharma, INC. | $500.25 | 2022-2024 | Tyrvaya |
| Rxsight INC | $372.94 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Eyevance Pharmaceuticals LLC | $333.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $317.90 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $293.44 | 2019-2021 | |
| Shire North American Group INC | $289.14 | 2019 | |
| New World Medical,INC. | $262.37 | 2020-2024 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Tarsus Pharmaceuticals, INC. | $215.64 | 2024-2025 | Xdemvy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $201.22 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $199.85 | 2019-2022 | |
| Harrow Eye, LLC | $180.22 | 2024 | Vevye |
| Carl Zeiss Meditec USA, INC. | $134.45 | 2023 | Artevo 800 |
| Beaver-Visitec International, INC. | $72.85 | 2023 | |
| Sight Sciences, INC. | $58.94 | 2021-2022 | |
| Horizon Therapeutics Plc | $43.66 | 2019 | |
| Eyepoint US, INC. | $42.88 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $23.11 | 2025 | Omidria |
| Halozyme INC | $17.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Passarelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.